BIOTON S.A. (7U5.F)

0.8010 -0.0010 (-0.12%) As of 08:10AM CEST. Market open.

BIOTON S.A.

ul. Poznanska 12
Macierzysz
Ozarów Mazowiecki 05-850
Poland
48 22 721 4000
https://www.bioton.pl

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 355

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jeremy Launders	President of the Management Board	N/A	N/A	N/A
Mr. Adam Tomasz Polonek	Member of Management Board	N/A	N/A	1976
Ms. Anna Grabowska	Senior Finance Manager	N/A	N/A	N/A
Mr. Michal Deptuch	Operations Director	N/A	N/A	N/A
Renata Prokopczyk	Chief Accountant	N/A	N/A	N/A
Ms. Kamila Musnicka	Director of Legal Department	N/A	N/A	N/A
Mr. Mateusz Patryk Kosecki	Head of Biolek Business Unit & CEO of Biolek Sp. Z O.O.	N/A	N/A	1975

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

Corporate Governance

BIOTON S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.